• 1. Excellent electrochemical performance of LiFe0.4Mn0.6PO4 microspheres produced using a double carbon coating process?
  Yong Ping Huang,Tao Tao,Zheng Chen,Wei Han,Ying Wu,Chunjiang Kuang,Shaoxiong Zhou,Ying Chen J. Mater. Chem. A, 2014,2, 18831-18837
• 2. Evolution of dealloying induced strain in nanoporous gold crystals?
  Ross Harder,David C. Dunand,Ian McNulty Nanoscale, 2017,9, 5686-5693
• 3. Evidence of field induced slow magnetic relaxation in cis-[Co(hfac)2(H2O)2] exhibiting tri-axial anisotropy with a negative axial component?
  Denis V. Korchagin,Elena A. Yureva,Alexander V. Akimov,Eugenii Ya. Misochko,Gennady V. Shilov,Artem D. Talantsev,Roman B. Morgunov,Alexander A. Shakin,Sergey M. Aldoshin,Boris S. Tsukerblat Dalton Trans., 2017,46, 7540-7548
• 4. Fe/Fe3C@C nanoparticles encapsulated in N-doped graphene–CNTs framework as an efficient bifunctional oxygen electrocatalyst for robust rechargeable Zn–air batteries?
  Zhiyan Chen,Nan Wu,Yaobing Wang,Bing Wang,Yingde Wang J. Mater. Chem. A, 2018,6, 516-526
• 5. Exciplex emission from the mixed dimer of naphthalene and 2-cyanonaphthalene in a supersonic jet
  Aloke Das,K. K. Mahato,Chayan K. Nandi,Tapas Chakraborty,Shridhar R. Gadre,Nikhil A. Gokhale Phys. Chem. Chem. Phys., 2002,4, 2162-2168

Tarenflurbil (CAS No. 51543-40-9): A Comprehensive Overview of Its Mechanism, Applications, and Research Advancements

Tarenflurbil, also known by its CAS No. 51543-40-9, is a small-molecule compound that has garnered significant attention in the field of neurodegenerative disease research. Originally developed as a selective amyloid-beta 42 (Aβ42) modulator, this compound has been extensively studied for its potential therapeutic effects in Alzheimer's disease (AD). The growing global burden of neurodegenerative disorders, coupled with the lack of effective treatments, has made Tarenflurbil a subject of intense scientific and clinical interest.

One of the most frequently searched questions about Tarenflurbil is: "How does Tarenflurbil work in Alzheimer's disease?" The compound functions by modulating the production of Aβ42, a peptide implicated in the formation of amyloid plaques, a hallmark of AD pathology. By reducing the levels of this toxic peptide, Tarenflurbil aims to slow disease progression. This mechanism aligns with the current focus on disease-modifying therapies, a hot topic in neurology and geriatric medicine.

Recent advancements in Tarenflurbil research have explored its potential beyond Alzheimer's disease. Studies suggest it may have applications in other neuroinflammatory conditions, such as Parkinson's disease and multiple sclerosis. This broader therapeutic potential has sparked debates in the scientific community, particularly regarding its pharmacokinetic properties and optimal dosing regimens. Researchers are also investigating whether Tarenflurbil could synergize with emerging immunotherapy approaches for neurodegenerative diseases.

The synthetic pathway of Tarenflurbil (CAS No. 51543-40-9) involves a series of carefully controlled chemical reactions to ensure high purity and bioactivity. Analytical techniques like HPLC and mass spectrometry are crucial for quality control during production. These technical aspects are often queried by pharmaceutical professionals searching for "Tarenflurbil synthesis protocol" or "CAS 51543-40-9 analytical methods".

From a clinical perspective, Tarenflurbil has undergone several phase II and III trials, with mixed results that continue to generate discussion. While initial studies showed promise in mild AD patients, later trials faced challenges in demonstrating significant cognitive benefits. These outcomes have led to important conversations about biomarker selection and patient stratification in neurodegenerative drug development—topics frequently searched by clinicians and researchers alike.

The future of Tarenflurbil research may lie in combination therapies and precision medicine approaches. With increasing interest in personalized treatment for neurodegenerative diseases, scientists are examining whether genetic factors influence response to Tarenflurbil. This aligns with current trends in searching for "personalized Alzheimer's treatments" and "biomarkers for drug response" in medical literature and AI-powered search platforms.

From a pharmaceutical chemistry standpoint, the structure-activity relationship (SAR) of Tarenflurbil continues to be refined. Medicinal chemists are particularly interested in modifications that might enhance its blood-brain barrier penetration or reduce potential off-target effects. These aspects are crucial for researchers querying "Tarenflurbil derivatives" or "CAS 51543-40-9 structural analogs" in scientific databases.

In conclusion, Tarenflurbil (CAS No. 51543-40-9) represents an important case study in neurodegenerative drug development. Its journey from bench to bedside—and the lessons learned along the way—continue to inform current research strategies. As the scientific community seeks answers to pressing questions about disease modification in Alzheimer's and related disorders, Tarenflurbil remains a valuable compound for understanding both the challenges and opportunities in this critical therapeutic area.

• 75852-60-7([1,1'-Biphenyl]-3-aceticacid, 5-fluoro-a-methyl-)
• 80685-20-7([1,1'-Biphenyl]-4-aceticacid, 2-fluoro-4'-hydroxy-a-methyl-)
• 51543-39-6((S)-Flurbiprofen)
• 5104-49-4(Flurbiprofen)
• 17692-38-5(2-(3'-Fluoro-[1,1'-biphenyl]-4-yl)propanoic acid)
• 133214-12-7([1,1'-Biphenyl]-4-aceticacid, 2-fluoro-a-methyl-,copper(2+) salt (2:1))
• 51543-38-5(()-2-fluoro-α-methyl[1,1'-biphenyl]-4-acetic acid)
• 56767-76-1(Flurbiprofen Sodium)
• 5001-96-7((2-Fluoro-4-biphenyl)acetic Acid)
• 1185133-81-6(Flurbiprofen-d)